


# CLAIM AMENDMENTS

1. (Original) A compound of the formula



wherein

R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;

R<sup>1</sup> is hydrogen or halogen; or


R and R<sup>1</sup> when adjacent, together with the ring carbon atoms to which they are attached are  
 -CH=CH-CH=CH-;

R<sup>2</sup> and R<sup>2'</sup> are hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or

R<sup>2</sup> and R<sup>2'</sup> when adjacent, together with the ring carbons to which they are attached are  
 -CH=CH-CH=CH-, unsubstituted or substituted by one or two substituents selected from  
 lower alkyl or lower alkoxy;

R<sup>3</sup> and R<sup>3'</sup> are hydrogen, lower alkyl or cycloalkyl;


R<sup>4</sup> and R<sup>4'</sup> together with the N-atom to which they are attached form a 5 member nitrogen  
 containing heterocyclic ring of the structure



said heterocyclic ring having 0 or 1 additional hetero-atoms selected from sulfur, nitrogen and oxygen, said additional hetero-sulfur atom being a sulfonyl moiety;  
 $R^5$  is hydrogen, hydroxy, lower alkyl, -lower alkoxy,  $-(CH_2)_mOH$ ,  $-COOR^3$ ,  $-CON(R^3)_2$ ,  $-N(R^3)CO$ -lower alkyl or  $-C(O)R^3$ ;  
 $R^6$  is lower alkyl;  
 $X$  is  $-C(O)N(R^6)-$ ,  $-N(R^6)C(O)-$ ,  $-(CH_2)_mO-$ ,  $-O(CH_2)_m-$ ;  
 $n$  is 0, 1, 2, 3 or 4; and  
 $m$  is 1, 2 or 3;  
 or a pharmaceutically acceptable acid addition salt thereof.

2. (Original) The compound of claim 1 wherein R is methyl.
3. (Original) The compound of claim 1 wherein R is chloro.
4. (Currently Amended) The compound of claim 1 wherein  $R^2$  and  $R^{2'}$  are adjacent and taken together with the ~~fig~~ ring carbons to which they are attached to form the group  $-CH=CH-CH=CH-$ .


5. (Original) The compound of claim 1 having the structure



le

6. (Original) The compound of claim 5 wherein R is methyl.
7. (Original) The compound of claim 5 wherein R is chloro.
8. (Currently Amended) The compound of claim 5 wherein  $R^2$  and  $R^{2'}$  are adjacent and taken together with the rig ring carbons to which they are attached to form the group  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ .

9. (Original) The compound of claim 1 having the structure



Id .


10. (Original) The compound of claim 9 wherein R is methyl.
11. (Original) The compound of claim 9 wherein R is chloro.
12. (Original) The compound of claim 9 wherein  $R^2$  and  $R^{2'}$  are adjacent and taken together with the rig carbons to which they are attached to form the group  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ .

13. (Original) The compound (RS)-6-[3-(acetyl-methyl-amino)-1-oxo-pyrrolidin-1-yl]-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-4-o-tolyl-nicotinamide.

14. (Cancelled)

15. (Cancelled)

16. (New) A method of treating a disease selected from the group consisting of emesis, anxiety, depression, inflammatory bowel disease, and migraines in a patient having such disease, comprising administering an effective amount of a compound of formula



wherein

R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;

R<sup>1</sup> is hydrogen or halogen; or


R and R<sup>1</sup> when adjacent, together with the ring carbon atoms to which they are attached are  
-CH=CH-CH=CH-;

R<sup>2</sup> and R<sup>2'</sup> are hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or

R<sup>2</sup> and R<sup>2'</sup> when adjacent, together with the ring carbons to which they are attached are  
-CH=CH-CH=CH-, unsubstituted or substituted by one or two substituents selected from  
lower alkyl or lower alkoxy;

$R^3$  and  $R^{3'}$  are hydrogen, lower alkyl or cycloalkyl;

$R^4$  and  $R^{4'}$  together with the N-atom to which they are attached form a 5 member nitrogen containing heterocyclic ring of the structure



said heterocyclic ring having 0 or 1 additional hetero-atoms selected from sulfur, nitrogen and oxygen, said additional hetero-sulfur atom being a sulfonyl moiety;

$R^5$  is hydrogen, hydroxy, lower alkyl, -lower alkoxy,  $-(CH_2)_mOH$ ,  $-COOR^3$ ,  $-CON(R^3)_2$ ,  $-N(R^3)CO$ -lower alkyl or  $-C(O)R^3$ ;

$R^6$  is lower alkyl;

X is  $-C(O)N(R^6)-$ ,  $-N(R^6)C(O)-$ ,  $-(CH_2)_mO-$ ,  $-O(CH_2)_m-$ ;

n is 0, 1, 2, 3 or 4; and

m is 1, 2 or 3;

or a pharmaceutically acceptable acid addition salt thereof.

17. (New) A method according to claim 16, which is emesis.

18. (New) A method according to claim 16, which is anxiety.

19. (New) A method according to claim 16, which is depression.

20. (New) A method according to claim 16, which is inflammatory bowel disease.

21. (New) A method according to claim 16, which is ulcerative colitis.

Serial No. 10/616,276  
Filed: July 9, 2003

22. (New) A method according to claim 16, which is Crohn's disease.
23. (New) A method according to claim 16, which is migraines.